Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Fluent Inc
COGT | US
32.26
USD-0.50
-1.53%
COGT | US
About Fluent Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
03/06/2026
Close
32.26
Open
32.80
High
32.80
Low
31.43
Cogent Biosciences Inc. a biotechnology company focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486) a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis as well as other mutations in KIT exon 17 which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research development and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences Inc. in October 2020. Cogent Biosciences Inc. was incorporated in 2014 and is headquartered in Waltham Massachusetts.
View LessCOGT | US
Risk
41.9
Sharpe
3.59
Luna's Score
51/100
Recommendation
Hold
Luna says (COGT | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
50.6%1 month
41.9%3 months
44.0%6 months
45.1%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.92
Debt to equity
0.05
Debt to assets
0.04
Ent. to EBITDA
-3.89
Ent. to rev.
925.41
PEG
-
Other Fundamentals
EBITDA
-242.22M
MarketCap
3.53B
MarketCap(USD)
3.53B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-100.00
Ret. on equity
-62.92
Short ratio
8.42
Short perc.
8.40
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
4.63
Range1M
6.64
Range3M
8.54
Volumes: Market Activity
Rel. volume
1.18
Price X volume
79.77M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.89 | - | Cheaper |
| Ent. to Revenue | 925.41 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.92 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 43.96 | - | Lower Risk |
| Debt to Equity | 0.05 | -1.23 | Expensive |
| Debt to Assets | 0.04 | 0.25 | Cheaper |
| Market Cap | 3.53B | - | Par |
